PharmaCyte Biotech, Inc. (PMCB) › Operating IncomePharmaCyte Biotech, Inc. (PMCB) — Operating IncomeAnnual figures by period end, from SEC filings.2012-04-30: -$1.95M2013-04-30: -$1.68M2014-04-30: -$18.98M2015-04-30: -$13.26M2016-04-30: -$6.07M2017-04-30: -$4.44M2018-04-30: -$6.98M2019-04-30: -$4.10M2020-04-30: -$3.83M2021-04-30: -$3.62M2022-04-30: -$4.39M2023-04-30: -$6.46M2024-04-30: -$8.52M2025-04-30: -$4.38M2026-04-30: -$6.85M-$6.85M2012-04-30Operating Income (USD)2026-04-30Period endedOperating IncomeChange YoYSource filing2026-04-30-$6.85M—2026-07-29From 2025-05-012025-04-30-$4.38M—2026-07-29From 2024-05-012024-04-30-$8.52M—2025-08-11From 2023-05-012023-04-30-$6.46M—2024-08-13From 2022-05-012022-04-30-$4.39M—2023-07-31From 2021-05-012021-04-30-$3.62M—2022-07-28From 2020-05-012020-04-30-$3.83M—2021-08-10From 2019-05-012019-04-30-$4.10M—2020-08-13From 2018-05-012018-04-30-$6.98M—2019-08-13From 2017-05-012017-04-30-$4.44M—2018-07-20From 2016-05-012016-04-30-$6.07M—2017-07-27From 2015-05-012015-04-30-$13.26M—2016-07-29From 2014-05-012014-04-30-$18.98M—2016-07-29From 2013-05-012013-04-30-$1.68M—2016-01-19From 2012-05-012012-04-30-$1.95M—2013-07-29From 2011-05-01Other metrics: RevenueCost of RevenueGross ProfitNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityCash & EquivalentsOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per ShareWeighted Average Diluted SharesEPS (Basic)